

# Giovanna Gallo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9500885/giovanna-gallo-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

260  
citations

9  
h-index

12  
g-index

61  
ext. papers

445  
ext. citations

3.5  
avg, IF

3.93  
L-index

#	Paper	IF	Citations
44	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention.. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2022</b> , 29, 91	2.9	1
43	Hypertension and COVID-19: Current Evidence and Perspectives.. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2022</b> , 29, 115	2.9	2
42	Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy.. <i>Heart</i> , <b>2022</b> ,	5.1	1
41	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 798958	4.9	10
40	The Natriuretic Peptides for Hypertension Treatment. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2021</b> , 1	2.9	3
39	Relationship Between Cardiorespiratory Fitness, Baseline Blood Pressure and Hypertensive Response to Exercise in the Ferrari Corporate Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2021</b> , 29, 81	2.9	2
38	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 1992-1994	9.9	1
37	Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, e141-e149	3	3
36	Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. <i>Journal of Human Hypertension</i> , <b>2021</b> ,	2.6	2
35	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2021</b> , 28, 255-262	2.9	1
34	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2021</b> , 28, 325-326	2.9	
33	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , <b>2021</b> , 327, 138-145	3.2	12
32	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 643721	4.6	4
31	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 652163	4.6	6
30	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , <b>2021</b> ,	1.6	1
29	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	9
28	Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3

27	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , <b>2020</b> , 316, 172-179	3.2	8
26	To whom recommend intensive treatment for hypertension?. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, E167-E172	1.5	1
25	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 932-943	3.3	2
24	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 371-380	3.7	11
23	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, L166-L169	1.5	1
22	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
21	Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 616564	5.4	2
20	Risk stratification in heart failure with mild reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 59-64	3.9	1
19	New approach to blood pressure control: Triple combination pill. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 30, 72-77	6.9	5
18	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. <i>International Journal of Cardiology</i> , <b>2019</b> , 291, 105-111	3.2	3
17	Molecular and clinical implications of natriuretic peptides in aortic valve stenosis. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2019</b> , 129, 266-271	5.8	3
16	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , <b>2019</b> , 124, 972-974	15.7	3
15	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , <b>2019</b> , 21, 85	4.7	6
14	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2019</b> , 286, 127-133	3.2	8
13	Aspirin in primary prevention: Nothing else matters like hypertension. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 2298-2299	1.9	1
12	Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes. <i>Oncotarget</i> , <b>2018</b> , 9, 35028-35040	3.3	10
11	Is early and fast blood pressure control important in hypertension management?. <i>International Journal of Cardiology</i> , <b>2018</b> , 254, 328-332	3.2	29
10	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2018</b> , 25, 327-341	2.9	12

9	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. <i>International Journal of Cardiology</i> , <b>2018</b> , 268, 27-33	3.2	20
8	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2017</b> , 24, 313-329	2.9	7
7	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2017</b> , 24, 331-339	2.9	6
6	[OP.3C.01] COMPARISON BETWEEN EUROPEAN SYSTEMATIC CORONARY RISK EVALUATION AND ITALIAN CUORE ALGORITHMS IN ADULT OUTPATIENTS FOLLOWED BY GENERAL PRACTITIONERS AND SPECIALISED CENTRES. <i>Journal of Hypertension</i> , <b>2017</b> , 35, e30	1.9	
5	[OP.6A.06] PREVALENCE AND CLINICAL CHARACTERISTICS OF TRUE MASKED HYPERTENSION COMPARED TO REVERSE AND ISOLATED NOCTURNAL MASKED HYPERTENSION. <i>Journal of Hypertension</i> , <b>2017</b> , 35, e56	1.9	
4	[PP.01.17] ADDING HYPERTENSION-RELATED MARKERS OF ORGAN DAMAGE TO RISK SCORE MODELS IMPROVES CARDIOVASCULAR RISK ASSESSMENT. <i>Journal of Hypertension</i> , <b>2017</b> , 35, e97	1.9	
3	[PP.04.18] COMPARISON AMONG DIFFERENT ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY. <i>Journal of Hypertension</i> , <b>2017</b> , 35, e116	1.9	
2	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. <i>Atherosclerosis</i> , <b>2016</b> , 246, 214-20	3.1	17
1	Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. <i>Data in Brief</i> , <b>2016</b> , 7, 1409-12	1.2	5